JPH0637379B2 - Topical for treatment of periodontal disease - Google Patents

Topical for treatment of periodontal disease

Info

Publication number
JPH0637379B2
JPH0637379B2 JP62010221A JP1022187A JPH0637379B2 JP H0637379 B2 JPH0637379 B2 JP H0637379B2 JP 62010221 A JP62010221 A JP 62010221A JP 1022187 A JP1022187 A JP 1022187A JP H0637379 B2 JPH0637379 B2 JP H0637379B2
Authority
JP
Japan
Prior art keywords
periodontal disease
treatment
agents
vitamin
toothpaste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP62010221A
Other languages
Japanese (ja)
Other versions
JPS63179823A (en
Inventor
賢児 萬野
昌樹 中垣
義之 石倉
昌宏 松浦
美保 増井
Original Assignee
サンスタ−株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンスタ−株式会社 filed Critical サンスタ−株式会社
Priority to JP62010221A priority Critical patent/JPH0637379B2/en
Publication of JPS63179823A publication Critical patent/JPS63179823A/en
Publication of JPH0637379B2 publication Critical patent/JPH0637379B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】 産業上の利用分野 本発明は口腔用組成物に関する。さらに詳しくは、本発
明はビタミンK2および/または塩酸ヒスチジンを含有
し血管強化作用にすぐれ、かつ歯肉炎等の歯周疾患の治
療などに有効な歯周疾患治療用外用剤に関する。
TECHNICAL FIELD OF THE INVENTION The present invention relates to oral compositions. More specifically, the present invention relates to an external preparation for the treatment of periodontal disease, which contains vitamin K 2 and / or histidine hydrochloride, has an excellent vascular strengthening action, and is effective for the treatment of periodontal diseases such as gingivitis.

従来の技術 近年、高齢化社会の到来に伴い、我国においても歯周疾
患の羅患率が増大し、これに対する治療および予防法の
確立が望まれている。歯周疾患は、歯肉溝内に歯垢、歯
石が蓄積して、歯肉を刺激し歯肉炎を引き起こすことに
より始まるとされている。炎症状態に陥った歯肉組織内
ではセロトニン、ブラジキニン、プロスタグランディン
などの種々のケミカルメディエーターが産生され、歯肉
溝上皮や歯肉毛細血管壁が脆弱化し透過性亢進などを引
き起こすため、歯肉溝滲出液の増大、歯肉粘膜からの出
血、歯肉溝の深化など種々の臨床症状が現れる。このよ
うな歯肉の炎症がさらに憎悪すると歯周組織が脆弱化
し、ついには組織の破壊をきたし、歯槽膿漏症に至る。
2. Description of the Related Art In recent years, with the advent of an aging society, the prevalence of periodontal disease has increased in Japan, and the establishment of treatment and prevention methods for it has been desired. Periodontal disease is said to start when plaque and tartar are accumulated in the gingival sulcus to stimulate the gingiva and cause gingivitis. Various chemical mediators such as serotonin, bradykinin, and prostaglandin are produced in the gingival tissue that is in an inflammatory state, and the gingival crevicular epithelium and the gingival capillary wall are weakened and cause increased permeability, which results in the gingival crevicular fluid. Various clinical symptoms such as increase, bleeding from the gingival mucosa, and deepening of the gingival sulcus appear. When such inflammation of the gingiva is further exacerbated, the periodontal tissue becomes weakened, which eventually causes destruction of the tissue, leading to alveolar pyorrhea.

かかる歯周疾患に対する治療は単なる外科療法が多く、
また薬効剤として消炎剤や抗菌剤が使用されているにす
ぎない。
Many treatments for such periodontal diseases are merely surgical therapy,
In addition, anti-inflammatory agents and antibacterial agents are only used as medicinal agents.

発明が解決しようとする問題点 このように従来、歯周疾患に用いられた薬効剤は消炎
剤、あるいは抗菌剤であり、脆弱化した組織自体を改善
する薬剤はなく、これを目的とした治療も行なわれてい
ない。
Problems to be Solved by the Invention As described above, the conventional medicinal agents used for periodontal disease are anti-inflammatory agents or antibacterial agents, and there is no agent for improving the weakened tissue itself, and treatment for the purpose. Has not been done.

本発明者らはかかる事情に鑑み、脆弱化した歯周組織を
改善すべく、組織の物理的刺激に対する抵抗力を強化す
る薬剤について鋭意研究を行なった結果、ビタミン
2、および塩酸ヒスチジンを局所投与することにより
歯周疾患の治療に著効があることを知り本発明を完成す
るに至った。
In view of such circumstances, the present inventors have conducted earnest research on a drug that enhances resistance of the tissue to physical stimulation in order to improve weakened periodontal tissue, and as a result, vitamin K 2 and histidine hydrochloride were locally applied. It was found that the administration of the drug has a remarkable effect on the treatment of periodontal disease, and the present invention has been completed.

問題点を解決するための手段 すなわち、本発明はビタミンK2および塩酸ヒスチジン
からなる群より選ばれた1種または2種の活性成分を含
有することを特徴とする歯周疾患治療用外用剤を提供す
るものである。
Means for Solving the Problems That is, the present invention provides an external preparation for the treatment of periodontal disease, which comprises one or two active ingredients selected from the group consisting of vitamin K 2 and histidine hydrochloride. It is provided.

本発明口腔用組成物に有効成分として配合されるビタミ
ンK2は従来、止血剤として知られており、一方塩酸ヒ
スチジンは潰瘍組織修復剤として知られているが、毛細
血管抵抗性を強化する作用を有することについては全く
知られていない。さらに、驚くべきことに、これら薬剤
を配合した組成物は経口投与では効果を示さず、局所投
与によってのみ効果を発現することが判明した。
Vitamin K 2 contained in the oral composition of the present invention as an active ingredient is conventionally known as a hemostatic agent, while histidine hydrochloride is known as an ulcer tissue repair agent, but it has an action to enhance capillary resistance. Nothing is known about having. Furthermore, it was surprisingly found that the composition containing these drugs showed no effect by oral administration, but exhibited an effect only by local administration.

本発明組成物の剤型としては、練歯磨、粉歯磨、液状歯
磨、洗口剤、軟膏剤、クリーム、パスタ、トローチ、チ
ューインガム、貼付剤などが挙げられる。
Examples of the dosage form of the composition of the present invention include toothpaste, powdered toothpaste, liquid toothpaste, mouthwash, ointment, cream, pasta, troche, chewing gum, patch and the like.

(A)つぎに、本発明組成物に配合する薬効剤(ビタミ
ンK2、塩酸ヒスチジン)の毛細血管強化作用および粘
膜剥離作用について試験した結果を示す。
(A) Next, the results of testing the capillary action and mucolytic effect of the pharmacological agents (vitamin K 2 and histidine hydrochloride) contained in the composition of the present invention are shown.

(i)毛細血管強化作用 (試験方法) wister系雄性ラット(7〜8週令)の腹部を除毛し、基剤
(マクロゴール軟膏、丸石製薬製)に被験薬効剤を配合
した軟膏を3日間塗布した。塗布は1日当たり5時間と
し、その間ラップおよびサージカルテープで覆いをし
た。塗布終了後、直径20mmの吸角を装着した紫斑計
(いわしや製)を用いて塗布部の皮膚を300mmHg
にて60秒間吸引し、5分後、直径10mmの円内にで
きた紫斑を計数した。一方、コントロール群には基剤の
みを同様に塗布した。つぎの基準により結果を比較し、
血管強化作用についての有効性を評価した。
(I) Capillary-enhancing action (Test method) The abdomen of male wister rats (7-8 weeks old) was depilated, and an ointment containing a test drug efficacy compound in a base (Macrogol ointment, manufactured by Maruishi Pharmaceutical Co., Ltd.) was used. It was applied for a day. Application was for 5 hours per day, during which time it was covered with wrap and surgical tape. After the application, the skin of the application area is 300 mmHg using a purpura meter (made by Iwashiya) equipped with an absorption angle of 20 mm in diameter.
After suctioning for 60 seconds, the purple spots formed in a circle having a diameter of 10 mm were counted after 5 minutes. On the other hand, the control group was similarly coated with only the base material. Compare the results according to the following criteria,
Efficacy for vascular strengthening was evaluated.

(評価基準) +++:極めて著効 ++ :著効 + :有効 ± :やや有効 − :無効 結果を第1表に示す。(Evaluation Criteria) ++: Extremely effective ++: Effective ++: Effective ±: Slightly effective −: Ineffective Table 1 shows the results.

(ii)粘膜剥離作用 (試験方法) 前記(i)と同様、薬効剤を配合した軟膏剤を用いて粘
膜剥離作用を検討した。
(Ii) Mucous membrane stripping action (Test method) Similar to (i) above, the mucous membrane stripping action was examined using an ointment containing a drug.

ゴールデンハムスター(雄、体重100〜116g)を
全身麻酔して頬袋に軟膏剤を塗布し、30分間放置した
後、25mlの蒸留水で水洗し、24時間放置した。その
後、頬袋組織を摘出し直ちに常法にしたがい組織標本を
作成し、光学顕微鏡観察して組織学的に粘膜の剥離が認
められるものを陽性+、認めれないものを陰性−とし
た。結果を第1表に示す。
A golden hamster (male, body weight 100 to 116 g) was general anesthetized, an ointment was applied to the cheek pouch, left for 30 minutes, washed with 25 ml of distilled water, and left for 24 hours. After that, the cheek pouch tissue was removed, and a tissue sample was immediately prepared according to a conventional method. Observation by an optical microscope was made to be positive + if the mucosal exfoliation was observed, and negative − if it was not observed. The results are shown in Table 1.

さらに、最終的な薬物の評価は、血管強化作用と粘膜剥
離作用の結果を合わせ考慮してつぎの基準で評価した。
Furthermore, the final evaluation of the drug was evaluated according to the following criteria in consideration of the results of the vascular strengthening action and the mucous membrane detaching action.

◎:非常に良い ○:良好 ×:不良 結果を第1表に示す。⊚: Very good ◯: Good x: Poor The results are shown in Table 1.

第1表より明らかなごとく、本発明組成物に有効成分と
して配合されるビタミンK2の配合量は、0.0001
〜10重量%であるのが好ましい。配合量が0.000
1重量%未満であると好ましい毛細血管抵抗性が得られ
ず、充分な治療効果が得られない。一方、配合量が10
重量%を越えると、粘膜剥離など副作用が生じて好まし
くない。
As is clear from Table 1, the amount of vitamin K 2 added to the composition of the present invention as an active ingredient is 0.0001.
It is preferably from 10 to 10% by weight. Compounding amount is 0.000
If it is less than 1% by weight, preferable capillary resistance cannot be obtained, and a sufficient therapeutic effect cannot be obtained. On the other hand, the compounding amount is 10
If it exceeds 5% by weight, side effects such as mucous membrane detachment occur, which is not preferable.

また塩素ヒスチジンの配合量も同様の理由により、0.
0001〜10重量%であるのが好ましい。
For the same reason, the compounding amount of chlorine histidine is 0.
It is preferably 0001 to 10% by weight.

(B)投与方法 さらに、これら本発明組成物に配合される薬効剤の血管
強化作用についてその投与方法の相違による特異性を比
較するためつぎの試験を行った。
(B) Administration Method Furthermore, the following test was conducted to compare the specificity of the drug-inhibiting agents contained in the composition of the present invention with respect to the blood vessel-enhancing action due to the difference in administration method.

wister系雄性ラット(7〜8週令)を用い、一方の群に
は前記試験(A)において総合結果が最も良かった、ビ
タミンK2および塩酸ヒスチジンの単独10重量%配合
または各々10重量%を配合したマクロゴール軟膏剤を同
様に塗布した。また、他方の群には薬効剤を0.5重量
%CMC溶液に懸濁し、局所での薬効剤濃度が同一とな
るように考慮して、一日一回、3日間経口投与した。各
動物の血管強化作用は試験(A)と同様に紫斑数により
評価した。結果を第2表に示す。
Wister male rats (7 to 8 weeks old) were used, and one group had the best overall result in the above test (A), containing vitamin K 2 and histidine hydrochloride alone at 10% by weight, or 10% by weight each. The formulated macrogol ointment was applied in the same manner. In the other group, the medicinal agent was suspended in a 0.5% by weight CMC solution, and was orally administered once a day for 3 days in consideration of the same concentration of the medicinal agent locally. The blood vessel strengthening effect of each animal was evaluated by the number of purpura as in the test (A). The results are shown in Table 2.

第2表より明らかなごとく、これら薬物の血管強化作用
は単独、併用いずれの場合においても局所に投与するこ
とによってのみ、その効果を発現することがわかる。
As is clear from Table 2, the blood vessel-enhancing action of these drugs, whether alone or in combination, is effective only when administered locally.

さらに、本発明組成物に配合される他の成分としては、
その歯周疾患治療用外用剤の種類に応じ適宜の公知の成
分が用いられる。
Furthermore, as other components to be added to the composition of the present invention,
Appropriate known ingredients are used depending on the type of the external preparation for treating periodontal disease.

例えば、練歯磨には、第二リン酸カルシウム、炭酸カル
シウム、リン酸水素カルシウムなどの研磨剤;カルボキ
シメチルセルロースナトリウム、ヒドロキシエチルセル
ロース、カラギーナン、ポリビニルアルコール、カルボ
キシビニルポリマーなどの粘結剤;グリセリン、ソルビ
トール、プロピレングリコール、ポリエチレングリコー
ル、1,3−ブチレングリコールなどの湿潤剤;ラウリ
ル硫酸ナトリウム、アウロイルサルコシンナトリウムな
どの発泡剤;さらに香味剤としてペパーミント、スペア
ミントなどの精油、メントールなどの香料、サッカリン
ナトリウムなどの甘味剤、また防腐剤が適宜配合され
る。
For example, for toothpaste, an abrasive such as dicalcium phosphate, calcium carbonate, calcium hydrogen phosphate; a binder such as sodium carboxymethyl cellulose, hydroxyethyl cellulose, carrageenan, polyvinyl alcohol, carboxy vinyl polymer; glycerin, sorbitol, propylene glycol. Wetting agents such as polyethylene glycol and 1,3-butylene glycol; effervescent agents such as sodium lauryl sulfate and auroyl sarcosine sodium; flavoring agents such as essential oils such as peppermint and spearmint; flavoring agents such as menthol; sweetening agents such as saccharin sodium; In addition, a preservative is appropriately mixed.

これらの成分を用いて、常法に従い製造する。It manufactures according to a conventional method using these components.

また、粉歯磨、液状歯磨、洗口剤、軟膏剤、クリーム、
パスタ、トローチ、チューインガム、貼付剤などについ
ても製品の性状に応じた成分を配合して常法に従い製造
する。
Also, powder toothpaste, liquid toothpaste, mouthwash, ointment, cream,
Pasta, troche, chewing gum, patch and the like are also prepared by blending the ingredients according to the properties of the product according to a conventional method.

なお、貼付剤は、口腔内の湿潤粘膜に貼付されて優れた
付着性を有し、投与薬剤の流出防止、口腔内粘膜損傷部
の被覆保護を行なうフィルム状の付着体からなる口腔内
製剤である。貼付剤の一例としては、粘膜に付着性を有
する水溶性高分子物質、例えばヒドロキシプロピルセル
ロース、カルボキシビニルポリマー等をフィルム状に成
形したものが挙げられる。
The patch is an intraoral preparation consisting of a film-like adherent which is applied to the moist mucous membrane of the oral cavity and has excellent adhesiveness, which prevents the outflow of the administered drug and protects the damaged portion of the mucous membrane in the oral cavity. is there. As an example of the patch, a water-soluble polymer substance having adhesiveness to mucous membrane, for example, hydroxypropyl cellulose, carboxyvinyl polymer or the like, which is formed into a film, can be mentioned.

本発明の歯周疾患治療用外用剤にはさらに各種の薬効剤
を配合してもよい。例えばクロルヘキシジン、テトラサ
イクリン、ミノサイクリン、ヨード、アクリノール、ヒ
ノキチオール、ペニシリンなどの抗菌剤;リゾチーム、
非ステロイド系抗炎症剤(インドメタシン、イブプロフ
ェン、フルルビプロフェン、ケトプロフェン、プラノプ
ロフェン、アスピリン、サリチル酸ナトリウム)、グリ
チルリチン酸塩、アズレン、グリチルリチンなどの消炎
剤;トラネキサム酸、ε−アミノカプロン酸、カルバゾ
クロム、アドレノクロム、バイオフラボノイドなどの止
血剤;ビタミンE誘導体(例えばビタミンEニコチネー
ト)などの血流改善剤;カンフル、オイゲノール、フェ
ノール、プロカイン、などの鎮痛剤;各種フっ素化合物
などの歯質強化剤、デキストラナーゼ、ムタナーゼなど
の歯垢形成抑制剤などが挙げられる。
The external preparation for treating periodontal disease of the present invention may further contain various medicinal agents. For example, antibacterial agents such as chlorhexidine, tetracycline, minocycline, iodine, acrinol, hinokitiol, penicillin; lysozyme,
Anti-inflammatory agents such as non-steroidal anti-inflammatory drugs (indomethacin, ibuprofen, flurbiprofen, ketoprofen, pranoprofen, aspirin, sodium salicylate), glycyrrhizinate, azulene, glycyrrhizin; tranexamic acid, ε-aminocaproic acid, carbazochrome, Hemostatic agents such as adrenochrome and bioflavonoids; blood flow improving agents such as vitamin E derivatives (eg vitamin E nicotinate); analgesics such as camphor, eugenol, phenol, procaine; tooth strengthening agents such as various fluorine compounds, Examples include plaque formation inhibitors such as dextranase and mutanase.

実施例 つぎに、実施例により本発明の歯周疾患治療用外用剤を
さらに具立的に説明する。
Example Next, the external preparation for treatment of periodontal disease of the present invention will be described more concretely with reference to Examples.

実施例1(練歯磨) 以下の組成により常法に基づき練歯磨を製造した。Example 1 (Toothpaste) A toothpaste having the following composition was produced by a conventional method.

実施例2〜3(練歯磨) ビタミンK2の代わりにつぎの薬効剤を配合した以外は
実施例1と同様にして練歯磨を製造した。
Examples 2 to 3 (toothpaste) Toothpaste was produced in the same manner as in Example 1 except that the following medicinal agents were added instead of vitamin K 2 .

実施例4(練歯磨) 下記の組成により実施例1と同様にして練歯磨を製造し
た。
Example 4 (Toothpaste) A toothpaste was produced in the same manner as in Example 1 with the following composition.

実施例5(粉歯磨) 下記の組成により常法にしたがい粉歯磨を製造した。 Example 5 (powder toothpaste) A powder toothpaste having the following composition was produced according to a conventional method.

実施例6(チューインガム) 下記組成により常法によりチューインガムを製造した。 Example 6 (Chewing gum) A chewing gum having the following composition was produced by a conventional method.

実施例7(マウスウォッシュ) 下記の組成により常法によりマウスウオッシュを製造し
た。
Example 7 (Mouthwash) A mouthwash having the following composition was produced by a conventional method.

実施例8(トローチ) 下記の組成により常法にしたがいトローチを製造した。 Example 8 (troche) A troche was produced according to a conventional method with the following composition.

実施例9(歯肉マッサージクリーム) 下記の組成により常法にしたがい歯肉マッサージクリー
ムを製造した。
Example 9 (gingival massage cream) A gingival massage cream was produced according to a conventional method with the following composition.

実施例10(うがい用錠剤) 下記の組成により常法にしたがいうがい用錠剤を製造し
た。
Example 10 (Tablet for mouthwash) A tablet for mouthwash was produced according to a conventional method with the following composition.

実施例11(口腔用パスタ) 下記の組成により常法にしたがい口腔用パスタを製造し
た。
Example 11 (Oral Pasta) An oral pasta was produced according to a conventional method with the following composition.

実施例12(軟膏状口腔用剤) 下記の組成により常法にしたがい軟膏状口腔用剤を製材
した。
Example 12 (Ointment-shaped oral preparation) An ointment-shaped oral preparation was made according to a conventional method with the following composition.

発明の効果 (使用例) 薬効剤の配合量を下記の通りとした以外は前記実施例1
1と同様に製造した口腔用パスタを用いて、つぎの方法
により歯肉炎の改善効果を試験した。試験対象者: 歯肉に炎症性の変化が認められる男性28名(22〜3
0歳)および女性12名(18〜25歳)を選び、炎症
症状がほぼ同程度になるように10名ずつの4群に分け
た。
EFFECTS OF THE INVENTION (Examples of Use) Example 1 above except that the compounding amounts of the medicinal agents were as follows.
Using the oral pasta produced in the same manner as in Example 1, the effect of improving gingivitis was tested by the following method. Test subjects: 28 men (22 to 3) with inflammatory changes in gingiva
0 year old) and 12 women (18 to 25 years old) were selected and divided into 4 groups of 10 people so that the inflammation symptoms were almost the same.

試験方法: 前記の4群をA〜D群とし、下記の処方による口腔用パ
スタを与えた。
Test method: The above 4 groups were designated as A to D groups, and oral pasta according to the following formulation was given.

A群 口腔用パスタにビタミンK1%配合 B群 口腔用パスタに塩酸ヒスチジン1%配合 C群 口腔用パスタにビタミンK1%および塩酸ヒス
チジン1%を配合 D群 コントロール:口腔用パスタ基剤のみ、薬物無配
合 被験者には同一の新しい歯ブラシを与え、毎食後、4週
間歯肉をマッサージさせた。ブラッシング方法は自由と
した。
Group A Oral pasta with 1% vitamin K 2 Group B Oral pasta with 1% histidine hydrochloride Group C Oral pasta with 1% vitamin K 2 and 1% histidine hydrochloride D group Control: Oral pasta base Only, the same drug-free subject was given the same new toothbrush and the gingiva was massaged for 4 weeks after each meal. Brushing method was free.

歯肉炎の改善効果の判定: PMA Index により評価した。すなわち、前歯部の乳
頭歯肉(P)、辺縁歯肉(M)、付着歯肉(A)の炎症
の有無により1(有)か0(無)のスコアを与え、その
合計点を各患者の指数とした。試験前と試験後における
各患者のスコアを比較し、つぎの式により改善率を算出
した。
Judgment of improvement effect on gingivitis: The PMA Index evaluated. That is, a score of 1 (present) or 0 (absent) is given depending on the presence or absence of inflammation of the anterior papilla (P), the marginal gingiva (M), and the attached gingiva (A), and the total score is the index of each patient And The scores of each patient before and after the test were compared, and the improvement rate was calculated by the following formula.

結果を第4表に示す。 The results are shown in Table 4.

第4表から明らかなごとく、A、BおよびC群はいずれ
もD群(コントロール)に対して有意な改善効果が認め
られる。
As is clear from Table 4, all of the A, B and C groups have a significant improving effect on the D group (control).

本発明の歯周疾患治療用外用剤は血管強化作用を示して
脆弱化した歯周組織を改善し、組織の物理的刺激に対す
る抵抗性を強化し、かつ歯肉炎等の歯周疾患の治療など
に著効が認められる。
The external preparation for the treatment of periodontal disease of the present invention shows a vascular strengthening effect to improve the weakened periodontal tissue, enhances the resistance of the tissue to physical stimulation, and treats periodontal diseases such as gingivitis, etc. A remarkable effect is recognized in.

フロントページの続き (56)参考文献 特開 昭57−171909(JP,A) 特開 昭61−15818(JP,A) 特開 昭60−25918(JP,A) 特開 昭62−201825(JP,A)Continuation of front page (56) Reference JP-A-57-171909 (JP, A) JP-A-61-15818 (JP, A) JP-A-60-25918 (JP, A) JP-A-62-201825 (JP , A)

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】ビタミンK2および塩酸ヒスチジンからな
る群より選ばれた1種または2種の活性成分を含有する
ことを特徴とする歯周疾患治療用外用剤。
1. An external preparation for treatment of periodontal disease, which comprises one or two active ingredients selected from the group consisting of vitamin K 2 and histidine hydrochloride.
【請求項2】ビタミンK2の含有量が0.0001〜1
0重量%である前記第(1)項の歯周疾患治療用外用
剤。
2. A vitamin K 2 content of 0.0001 to 1
The external preparation for treatment of periodontal disease according to the above (1), which is 0% by weight.
【請求項3】塩酸ヒスチジンの含有量が0.0001〜
10重量%である前記第(1)項の歯周疾患治療用外用
剤。
3. The histidine hydrochloride content of 0.0001-
The external preparation for treatment of periodontal disease according to item (1), which is 10% by weight.
JP62010221A 1987-01-19 1987-01-19 Topical for treatment of periodontal disease Expired - Lifetime JPH0637379B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62010221A JPH0637379B2 (en) 1987-01-19 1987-01-19 Topical for treatment of periodontal disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62010221A JPH0637379B2 (en) 1987-01-19 1987-01-19 Topical for treatment of periodontal disease

Publications (2)

Publication Number Publication Date
JPS63179823A JPS63179823A (en) 1988-07-23
JPH0637379B2 true JPH0637379B2 (en) 1994-05-18

Family

ID=11744220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62010221A Expired - Lifetime JPH0637379B2 (en) 1987-01-19 1987-01-19 Topical for treatment of periodontal disease

Country Status (1)

Country Link
JP (1) JPH0637379B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510391A (en) * 1993-10-22 1996-04-23 Mayapple Holdings, Llc Method of treating blood vessel disorders of the skin using vitamin K
JP3648587B2 (en) * 1998-03-04 2005-05-18 サンスター株式会社 Periodontal disease prevention or periodontal disease progression food composition
MX2007001384A (en) * 2004-08-02 2007-04-19 Glaxo Group Ltd Novel composition for xerostomia.
CN112778092B (en) * 2020-12-31 2023-03-24 玉溪健坤生物药业有限公司 Reduced vitamin K 2 Preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6025918A (en) * 1983-07-25 1985-02-08 Ajinomoto Co Inc Aqueous solution containing fat-soluble drug
JPS60171909A (en) * 1984-02-16 1985-09-05 Ricoh Co Ltd Endless belt driving device
JPS6115818A (en) * 1984-06-29 1986-01-23 Lion Corp Composition for oral cavity
JP2604135B2 (en) * 1986-02-28 1997-04-30 ライオン株式会社 Oral bone disease treatment

Also Published As

Publication number Publication date
JPS63179823A (en) 1988-07-23

Similar Documents

Publication Publication Date Title
JP2927850B2 (en) Topical preparations for the treatment of symptoms of teeth and their supporting tissues
US7115252B2 (en) Therapeutic compositions and methods of use thereof
US5709873A (en) Method of treating conditions of teeth and their supporting tissue
JP2009517382A (en) Oral care therapeutic and prophylactic compositions
WO2009106963A2 (en) Dental composition for preventing and treating stomatitis and mouth ulcers
US20070098650A1 (en) Dental formulation
BR112020002106B1 (en) GEL COMPOSITION, PREPARATION METHOD AND USE
US20050214230A1 (en) Novel stomatological gel
JP4824954B2 (en) Oral composition for the treatment of stomatitis
RU2550957C1 (en) Method of treating chronic generalised periodontitis
Steinberg et al. Dental drug-delivery devices: local and sustained-release applications
JPH09503504A (en) Use of azithromycin for the treatment of adult periodontitis and topical composition for this use
JPH0761933B2 (en) Oral composition
JPH0637379B2 (en) Topical for treatment of periodontal disease
JP3140050B2 (en) The use of ketorolac in the treatment of periodontal disease
JPH09291018A (en) Composition for oral cavity
JPH0637383B2 (en) Oral anti-inflammatory agent
JP2607945B2 (en) Periodontal tissue repair promoting composition
JP3667472B2 (en) Oral composition
US20070020200A1 (en) Therapeutic compositions and methods of use thereof
EP0973525A1 (en) Oral compositions containing fluocinonide
JP2806577B2 (en) Oral composition
JPH06345630A (en) Anti-inflammatory composition for oral cavity
JPS6256131B2 (en)
JP2895343B2 (en) Treatment for occlusal trauma